title: Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Hotta
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
authors.forename: Nagio
authors.initials: N
authors.lastname: Takigawa
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tabata
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors